Company overview
Biognosys provides next-generation proteomics solutions for pharmaceutical R&D and life sciences organizations, specializing in mass spectrometry-based protein analysis, proteogenomics, and biomarker discovery. Their platform enables comprehensive protein expression profiling, post-translational modification analysis, and quantitative proteome characterization to support drug development, target validation, and personalized medicine applications.
Proteomic Solutions is listed in the NovaPharmaNews Supplier Hub as a Life Science Reagents, Diagnostics & Testing partner serving United States & Americas. Core focus areas include proteomics services, mass spectrometry, biomarker discovery, drug development, protein quantification.
Industry categories: Life Science Reagents, Diagnostics & Testing. These tags help R&D, manufacturing, and procurement teams discover vendors aligned with their pipeline stage and compliance requirements.
Products and technologies associated with Proteomic Solutions include Mass Spectrometry — relevant for pharmaceutical discovery, process development, and GMP manufacturing workflows.
Structured facts
- Website
- https://www.biognosys.com/
- Categories
- Life Science Reagents, Diagnostics & Testing
- Markets served
- United States & Americas
- Keywords
- proteomics services, mass spectrometry, biomarker discovery, drug development, protein quantification
Products & technologies
Markets served
Industry categories
Company timeline
- — Profile published on NovaPharmaNews
- — Profile last updated
Related suppliers in category
Frequently asked questions
- What proteomics technologies and methodologies does Biognosys offer?
- Biognosys provides advanced mass spectrometry-based proteomics services including Data-Independent Acquisition (DIA) quantitative proteomics, phosphoproteomics, post-translational modification (PTM) analysis, and proteogenomics applications that combine proteomic data with genomic and transcriptomic information for comprehensive protein characterization.
- How can Biognosys support drug discovery and development programs?
- Biognosys enables therapeutic discovery through precise protein quantification in cells, tissues, and biofluids; identification of drug targets and biomarkers; analysis of protein variants and modifications; and evaluation of drug effects on protein systems. Their services support target validation, biomarker discovery, and personalized therapy development.
- What sample types and throughput capabilities does Biognosys support?
- Biognosys analyzes diverse sample types including cells, tissues, plasma, and formalin-fixed paraffin-embedded (FFPE) tissues. Their platform supports high-throughput analysis with capabilities to measure thousands of proteins across multiple samples simultaneously, enabling both discovery and screening studies with scalable workflows.
Related editorial coverage
- Biotech’s coming of age: AI, capital efficiency and China reshape the field
- Global hematology trials keep research patient-centered and regionally relevant
- America's Innovation Engine: Small and Mid-Sized Biotechs Drive U.S. Clinical Trials, FDA Filings
- Otsuka kidney drug data and Pfizer AI deal: Biopharma deal tracker
- FDA Extends Comment Period for Real-Time Clinical Trials Pilot, AI Use in Studies
- SGS Expands Bioanalytical Testing Capabilities in North America with Acquisition of CMIC, INC.
Explore lab tools and QA/QC resources for R&D teams.
